Melding bijwerking / Medische vraag
Decline in Psychotic Symptoms in addition to Cardiac and Metabolic Safety with Cariprazine after Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases

Decline in Psychotic Symptoms in addition to Cardiac and Metabolic Safety with Cariprazine after Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases

Decline in Psychotic Symptoms in addition to Cardiac and Metabolic Safety with Cariprazine after Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases2021-07-21T05:18:24+00:00
Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel

Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel

Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel2021-07-21T05:15:46+00:00
Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial

Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial

Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial2021-07-21T05:15:06+00:00
Recordati logo

This website contains information on Reagila® (cariprazine) which is based on the summary of product characteristics (smpc).
This website is intended to provide information exclusively to healthcare professionals in the european union and not intended for audience in the us or canada.
If you are not a healthcare professional, please leave the page and contact a healthcare professional.

2021/002/RecNL mei